William Blair & Company
ALXN

William Blair & Company’s Alexion Pharmaceuticals ALXN Stock Holding History

William Blair & Company’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-900
Closed -$110K – 1549
2017
Q2 		$110K Buy
900
+700
+350% +$81.5K ﹤0.01% 1421
2017
Q1 		$24K Buy
+200
New +$25.8K ﹤0.01% 1366

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

William Blair & Company's ALXN Position: Q3 2021 in Review

William Blair & Company sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 1,486 shares — an estimated $273K sold.

William Blair & Company first reported a position in ALXN in Q2 2013 and held it in 27 quarters. The position peaked at $3.57M in Q4 2015. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • William Blair & Company reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • William Blair & Company sold 1,486 Alexion Pharmaceuticals shares in Q3 2021, an estimated $273K.
  • William Blair & Company first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 27 quarters.
  • William Blair & Company's Alexion Pharmaceuticals position peaked at $3.57M in Q4 2015.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on William Blair & Company's 13F filing for Q3 2021, filed 12 Nov 2021.